Live recombinant Listeria monocytogenes as an immunotherapeutic agent for experimental tumors
- 1 December 1995
- journal article
- editorial
- Published by Elsevier in Trends in Microbiology
- Vol. 3 (12) , 451-452
- https://doi.org/10.1016/s0966-842x(00)89005-8
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Listeria monocytogenes: A Live Vector Able to Deliver Heterologous Protein Within the Cytosol and to Drive a CD8 Dependent T Cell ResponseBiologicals, 1995
- Co‐expression of B7‐1 and ICAM‐1 on tumors is required for rejection and the establishment of a memory responseEuropean Journal of Immunology, 1995
- Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunology Today, 1995
- Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokinesImmunity, 1995
- Cancer therapy: Less blood means more sanguinityCurrent Biology, 1995
- Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.The Journal of Experimental Medicine, 1994
- The implications of angiogenesis for the biology and therapy of cancer metastasisCell, 1994
- The CD44 Adhesion Molecule and MetastasisCritical Reviews™ in Oncogenesis, 1994
- Tumor Cell Interactions with the Extracellular Matrix During Invasion and MetastasisAnnual Review of Cell Biology, 1993
- Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenesNature, 1991